Bernd Giebel studied biology at the University zu Köln and received his PhD in 1996 at the Institute for Developmental Biology in Köln. 1999 he moved to the Heinrich-Heine-University of Düsseldorf, started to work with human hematopoietic stem and progenitor cells and set up his own group. In 2008 he moved to the Institute of Transfusion Medicine at the University Hospital Essen. Here, he continues his studies on human somatic stem cells. As a second topic, in 2009, his group started to work on purification and analysis methods for EVs, setting a focus on mesenchymal stem/stromal cell-derived EVs (MSC-EVs). Together with collaboration partners the group demonstrated the therapeutic potential of prepared MSC-EVs in a human GvHD-patient and in different animal models. It is the current goal to optimize the MSC-EV production and characterization process to efficiently translate MSC-EVs into the clinics.
B Giebel was a member of the ME-HAD COST Action and led the working group Diagnostic & Therapeutic Potential of Microvesicles and Exosomes (ME). Since 2012 he is an active member of the International Society of Extracellular Vesicles (ISEV) and coordinated an ISEV position paper regarding the therapeutic application of EVs. Furthermore, he is the president of the German Society of Extracellular Vesicles (GSEV), which he founded together with other German EV experts on March 2nd 2017. According to his expertise, he became part of the scientific advisory board of two SME companies, Innovex Therapeutics and EVOX. More recently B. Giebel got involved in the International Society of Gene and Cell Therapy (ISCT) now heading an exosome working group intending to promote translation of MSC-EVs into the clinics.